ARVO: DOT spectacle lenses cut myopia progression >1.00D at 24 months, SightGlass reports

Myopia-control glasses are having a real moment — and SightGlass Vision just gave that category a bigger talking point. At ARVO 2026 in Denver, the company presented 24-month d(reviewofmm.com)d myopia progression versus standard single-vision glasses. The headline number is the one clinics will repeat: in children ages 6 to 10, the aver(optometrytimes.com)ningful. (reviewofmm.com) ### What are DOT lenses? DOT stands for Di(reviewofmm.com)sual signal. The lenses use thousands of tiny light-scattering elements to reduce retinal contrast, because the company’s theory is that overly sharp contrast can help drive the abnormal eye growth behind myopia progression. Regular vision correction still happens through a clear central zone, so the treatment is built into something that still looks like ordinary glasses. (iovs.arvojournals.org) ### What exactly was new at ARVO? The new piece was the 24-month readout from the CATHAY study in Chin(reviewofmm.com)00D less myopia progression on average than children wearing conventional single-vision lenses after two years. In the full study population, ages 6 to 13, DOT lenses slowed average myopia progression by 0.78D and average axial-length growth by 0.40 mm compared with controls. (reviewofmm.com) ### Why does axial length matter? Because nearsightedness is not just a glasses prescription problem. The more the eye elongates, the more th(iovs.arvojournals.org)lications like myopic maculopathy, retinal detachment, and glaucoma. So when myopia-control studies report both diopters and axial length, the axial-length number is doing a lot of the heavy lifting. It is the structural measure, not just the optical one. (optometrytimes.com) ### Is this coming out of nowhere? Not really. The 2026 results build on (reviewofmm.com)rolled 195 children across five Chinese hospital sites, and DOT lenses reduced myopia progression by 0.48D and axial elongation by 0.26 mm versus controls at one year — roughly 75% reductions on both measures. So the two-year update matters partly because it suggests the effect did not vanish after the first year. (iovs.arvojournals.org) ### Why are clinics excited about glasses-based control? Basically, glasses are e(optometrytimes.com)ns can be prescribed in a routine workflow and worn during the day like any other pair of glasses. That does not make it automatically better, but it does make it easier to scale if efficacy is good enough and families actually stick with wear time. (reviewofmm.com) ### What’s the catch? The catch is that these are company-highlighted conference data, not yet a full peer-reviewed 24-month paper in hand. (iovs.arvojournals.org)hile the all-comers result is lower. And myopia control always lives or dies on real-world behavior: how long kids wear the lenses, whether they switch treatments, and how durable the effect looks across different populations. (reviewofmm.com) ### Where does this leave the field? It leaves spectacle-based myopia control looking more credible than it did a few years ago. DOT lenses are not the on(reviewofmm.com)oking spectacles can produce clinically meaningful slowing of progression, not just marginal improvements. That is a big deal because childhood myopia is rising fast, and the easiest treatment to distribute often wins. (reviewofmm.com) ### Bottom line? SightGlass brought a strong two-year number to ARVO 2026, and the number that will stick is simple: more than 1.00D saved in youn(reviewofmm.com)t does make DOT lenses harder to dismiss as just another clever spectacle design.